Abstract 1671P
Background
The rise of the internet has transformed communication and healthcare, allowing easy access to sensitive medical test results. However, this practice lacks regulation. Breast cancer, the most common cancer in women, has seen improved survival rates, leading to more individuals living with the disease. Patients accessing their results online can pose challenges for oncologists due to the anxiety stemming from this constant access. Studies show conflicting outcomes regarding the emotional impact of this access, ranging from increased patient engagement to heightened anxiety. This study aims to investigate whether online receipt of sensitive results can worsen the emotional health of oncology patients, for instance, by intensifying anxiety symptoms.
Methods
This cross-sectional study employed a questionnaire with four sections to assess patients diagnosed with breast cancer within five years. The questionnaire covered demographic information, online test result access habits, anxiety levels during result anticipation, and validated screening tools for personality disorders (PID-5-BF), anxiety (GAD-7), and depression (PHQ-9). Sample size estimation for confidence interval calculations targeted 385 patients. The current analysis includes data from 198 respondents.
Results
Among the 198 participants, 196 (99%) were female, with only 2 (1%) being male. The majority (75.3%) received their breast cancer diagnosis within the past 1 to 5 years. In terms of cancer staging, 41.4% had early-stage disease (Stages I-III), while 57.6% had advanced-stage disease (Stage IV). Concerning online result access, 25.3% reported infrequent online result checks, while 74.2% confirmed habitual checking. During result anticipation, 64.6% expressed anxiety, primarily described as mild (62.2%). Statistical analyses indicated no significant association between online result access behavior and anxiety levels (p=0.609), anxiety disorders (p=0.411), or depressive disorders (p=0.484).
Conclusions
This interim analysis did not reveal a correlation between receiving potentially sensitive test results online and patient anxiety. Recruitment is ongoing and on target to produce a final analysis in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11